{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:28:19Z","timestamp":1793838499966,"version":"4.6.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04692-0","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:02:46Z","timestamp":1792400566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-3748","authenticated-orcid":false,"given":"Florence","family":"Magrangeas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-2238","authenticated-orcid":false,"given":"Mia","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bessonneau-Gaborit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-2055","authenticated-orcid":false,"given":"Jennifer","family":"Derrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-089X","authenticated-orcid":false,"given":"C\u00e9line","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gu\u00e9rin-Charbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-5682","authenticated-orcid":false,"given":"Mehmet Kemal","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Intergroupe Francophone du My\u00e9lome (IFM)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-7724","authenticated-orcid":false,"given":"Ludovic","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-312X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Minvielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-2839","authenticated-orcid":false,"given":"Eric","family":"Letouz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"4692_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91\u2013101 (2014).","journal-title":"Cancer Cell"},{"key":"4692_CR2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker, B. A. et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132, 587\u2013597 (2018).","journal-title":"Blood"},{"key":"4692_CR3","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli, N. et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 32, 2604\u20132616 (2018).","journal-title":"Leukemia"},{"key":"4692_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2018","unstructured":"Shah, V. et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32, 102\u2013110 (2018).","journal-title":"Leukemia"},{"key":"4692_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09555-6","volume":"10","author":"BG Barwick","year":"2019","unstructured":"Barwick, B. G. et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat. Commun. 10, 1911 (2019).","journal-title":"Nat. Commun."},{"key":"4692_CR6","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","volume":"38","author":"MK Samur","year":"2020","unstructured":"Samur, M. K. et al. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group. J. Clin. Oncol. 38, 3107\u20133118 (2020).","journal-title":"J. Clin. Oncol."},{"key":"4692_CR7","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura, F. et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat. Cancer 4, 1660\u20131674 (2023).","journal-title":"Nat. Cancer"},{"key":"4692_CR8","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget, S. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat. Genet. 56, 1878\u20131889 (2024).","journal-title":"Nat. Genet."},{"key":"4692_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","volume":"118","author":"F Magrangeas","year":"2011","unstructured":"Magrangeas, F., Avet-Loiseau, H., Munshi, N. C. & Minvielle, S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 118, 675\u2013678 (2011).","journal-title":"Blood"},{"key":"4692_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3997","volume":"5","author":"N Bolli","year":"2014","unstructured":"Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).","journal-title":"Nat. Commun."},{"key":"4692_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2015).","journal-title":"Nat. Commun."},{"key":"4692_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11680-1","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 10, 3835 (2019).","journal-title":"Nat. Commun."},{"key":"4692_CR13","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"4692_CR14","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl, A. et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116, 2543\u20132553 (2010).","journal-title":"Blood"},{"key":"4692_CR15","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy, J. D. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"4692_CR16","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux, O. et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome. J. Clin. Oncol. 26, 4798\u20134805 (2008).","journal-title":"J. Clin. Oncol."},{"key":"4692_CR17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","volume":"25","author":"X Agirre","year":"2015","unstructured":"Agirre, X. et al. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Res. 25, 478\u2013487 (2015).","journal-title":"Genome Res."},{"key":"4692_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00938-3","volume":"13","author":"J Derrien","year":"2021","unstructured":"Derrien, J. et al. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability. Genome Med. 13, 127 (2021).","journal-title":"Genome Med."},{"key":"4692_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat. Rev. Clin. Oncol. 22, 680\u2013700 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4692_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29\u201338 (2019).","journal-title":"Lancet"},{"key":"4692_CR21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301\u2013313 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4692_CR22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai, E. K. et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J. Clin. Oncol. 43, 1279\u20131288 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4692_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt, L. B. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J. Clin. Oncol. 42, 26\u201337 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4692_CR24","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau, C. et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143, 2029\u20132036 (2024).","journal-title":"Blood"},{"key":"4692_CR25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","volume":"146","author":"A Perrot","year":"2025","unstructured":"Perrot, A. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood 146, 52\u201361 (2025).","journal-title":"Blood"},{"key":"4692_CR26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot, A. et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N. Engl. J. Med. 393, 425\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4692_CR27","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132, 2456\u20132464 (2018).","journal-title":"Blood"},{"key":"4692_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva, S. et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 11, 106 (2021).","journal-title":"Blood Cancer J."},{"key":"4692_CR29","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R. et al. International staging system for multiple myeloma. J. Clin. Oncol. 23, 3412\u20133420 (2005).","journal-title":"J. Clin. Oncol."},{"key":"4692_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01550-7","author":"F Magrangeas","year":"2026","unstructured":"Magrangeas, F. et al. Expression profile of38, CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-026-01550-7 (2026).","journal-title":"Blood Cancer J."},{"key":"4692_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41586-021-04043-8","volume":"599","author":"J Frazer","year":"2021","unstructured":"Frazer, J. et al. Disease variant prediction with deep generative models of evolutionary data. Nature 599, 91\u201395 (2021).","journal-title":"Nature"},{"key":"4692_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"4692_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","volume":"589","author":"N Yusufova","year":"2021","unstructured":"Yusufova, N. et al. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature 589, 299\u2013305 (2021).","journal-title":"Nature"},{"key":"4692_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ng.2508","volume":"45","author":"K De Keersmaecker","year":"2013","unstructured":"De Keersmaecker, K. et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat. Genet. 45, 186\u2013190 (2013).","journal-title":"Nat. Genet."},{"key":"4692_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41375-018-0176-z","volume":"33","author":"KR Kampen","year":"2019","unstructured":"Kampen, K. R. et al. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia 33, 319\u2013332 (2019).","journal-title":"Leukemia"},{"key":"4692_CR36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen, G. W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90\u2013104 (2013).","journal-title":"Cancer Cell"},{"key":"4692_CR37","first-page":"E4762","volume":"111","author":"D Yang","year":"2014","unstructured":"Yang, D. et al. Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proc. Natl Acad. Sci. USA 111, E4762\u2013E4768 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4692_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9746","volume":"6","author":"ZN Wee","year":"2015","unstructured":"Wee, Z. N. et al. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat. Commun. 6, 8746 (2015).","journal-title":"Nat. Commun."},{"key":"4692_CR39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood.2022018718","volume":"142","author":"J Bennett","year":"2023","unstructured":"Bennett, J. et al. Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML. Blood 142, 989\u20131007 (2023).","journal-title":"Blood"},{"key":"4692_CR40","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/onc.2011.344","volume":"31","author":"EE Santo","year":"2012","unstructured":"Santo, E. E. et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 31, 1571\u20131581 (2012).","journal-title":"Oncogene"},{"key":"4692_CR41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2422.2422","volume":"126","author":"H Quentmeier","year":"2015","unstructured":"Quentmeier, H. et al. FOXR1 activation in B-cell lymphoma. Blood 126, 2422 (2015).","journal-title":"Blood"},{"key":"4692_CR42","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/0008-5472.CAN-21-0791","volume":"81","author":"R Gillani","year":"2021","unstructured":"Gillani, R. et al. Gene fusions create partner and collateral dependencies essential to cancer cell survival. Cancer Res. 81, 3971\u20133984 (2021).","journal-title":"Cancer Res."},{"key":"4692_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"4692_CR44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"4692_CR45","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani, S. Z. et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 6, e448\u2013e458 (2019).","journal-title":"Lancet Haematol."},{"key":"4692_CR46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2643-3230.BCD-23-0208","volume":"5","author":"S Thibaud","year":"2024","unstructured":"Thibaud, S. et al. Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes. Blood Cancer Discov. 5, 428\u2013441 (2024).","journal-title":"Blood Cancer Discov."},{"key":"4692_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15740-9","volume":"11","author":"EH Rustad","year":"2020","unstructured":"Rustad, E. H. et al. Timing the initiation of multiple myeloma. Nat. Commun. 11, 1917 (2020).","journal-title":"Nat. Commun."},{"key":"4692_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41588-018-0073-4","volume":"50","author":"W Zhou","year":"2018","unstructured":"Zhou, W. et al. DNA methylation loss in late-replicating domains is linked to mitotic cell division. Nat. Genet. 50, 591\u2013602 (2018).","journal-title":"Nat. Genet."},{"key":"4692_CR49","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41586-025-09374-4","volume":"645","author":"C Gabbutt","year":"2025","unstructured":"Gabbutt, C. et al. Fluctuating DNA methylation tracks cancer evolution at clinical scale. Nature 645, 764\u2013773 (2025).","journal-title":"Nature"},{"key":"4692_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"4692_CR51","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/bioinformatics\/bty388","volume":"34","author":"J Shinde","year":"2018","unstructured":"Shinde, J. et al. Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics 34, 3380\u20133381 (2018).","journal-title":"Bioinformatics"},{"key":"4692_CR52","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"4692_CR53","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"4692_CR54","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cort\u00e9s-Ciriano","year":"2020","unstructured":"Cort\u00e9s-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331\u2013341 (2020).","journal-title":"Nat. Genet."},{"key":"4692_CR55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029\u20131041 (2017).","journal-title":"Cell"},{"key":"4692_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-244","volume":"14","author":"H Zhang","year":"2013","unstructured":"Zhang, H., Meltzer, P. & Davis, S. RCircos: an R package for Circos 2D track plots. BMC Bioinformatics 14, 244 (2013).","journal-title":"BMC Bioinformatics"},{"key":"4692_CR57","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu, Z. Complex heatmap visualization. Imeta 1, e43 (2022).","journal-title":"Imeta"},{"key":"4692_CR58","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"4692_CR59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4692_CR60","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"4692_CR61","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296\u2013303 (2005).","journal-title":"Blood"},{"key":"4692_CR62","doi-asserted-by":"crossref","first-page":"27854","DOI":"10.18632\/oncotarget.15718","volume":"8","author":"CK Stein","year":"2017","unstructured":"Stein, C. K. et al. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8, 27854\u201327867 (2017).","journal-title":"Oncotarget"},{"key":"4692_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"4692_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"4692_CR65","volume":"53","author":"Y Chen","year":"2025","unstructured":"Chen, Y., Chen, L., Lun, A. T. L., Baldoni, P. L. & Smyth, G. K. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Res. 53, gkaf018 (2025).","journal-title":"Nucleic Acids Res."},{"key":"4692_CR66","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"4692_CR67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"4692_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas, B. J. et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 20, 213 (2019).","journal-title":"Genome Biol."},{"key":"4692_CR69","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","volume":"27","author":"F Krueger","year":"2011","unstructured":"Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571\u20131572 (2011).","journal-title":"Bioinformatics"},{"key":"4692_CR70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"4692_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2012-13-10-r87","volume":"13","author":"A Akalin","year":"2012","unstructured":"Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).","journal-title":"Genome Biol."},{"key":"4692_CR72","doi-asserted-by":"crossref","first-page":"e202503514","DOI":"10.26508\/lsa.202503514","volume":"9","author":"N Loyfer","year":"2026","unstructured":"Loyfer, N., Rosenski, J. & Kaplan, T. wgbstools: a computational suite for DNA methylation sequencing data analysis. Life Sci. Alliance 9, e202503514 (2026).","journal-title":"Life Sci. Alliance"},{"key":"4692_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"4692_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).","journal-title":"BMC Bioinformatics"},{"key":"4692_CR75","doi-asserted-by":"publisher","unstructured":"Magrangeas, F. et al. Processed data for: Molecular predictors of minimal residual disease in newly-diagnosed multiple myeloma treated with quadruplet therapy. Zenodo https:\/\/doi.org\/10.5281\/ZENODO.22108924 (2026).","DOI":"10.5281\/ZENODO.22108924"},{"key":"4692_CR76","doi-asserted-by":"publisher","unstructured":"Magrangeas, F. et al. Code for: Molecular predictors of minimal residual disease in newly-diagnosed multiple myeloma treated with quadruplet therapy. Zenodo https:\/\/doi.org\/10.5281\/ZENODO.22072688 (2026).","DOI":"10.5281\/ZENODO.22072688"}],"updated-by":[{"DOI":"10.1038\/s41591-026-04792-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:00:00Z","timestamp":1793664000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04692-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04692-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04692-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:04:38Z","timestamp":1793837078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04692-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":76,"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04692-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04792-x","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04792-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}